We want to challenge and improve today's standardized treatments with the help of our AI technology. In the field of oncology, we create truly personalized therapies where one size fits one, and only one. Within infectious diseases, we use the technology to design next-generation vaccines to address unmet medical needs.
Modern medicine is advancing rapidly, yet too many people still die of cancer, drug-resistant bacteria, and other infectious diseases. The demand for new, efficient drugs has never been higher and will only grow. Every day, our artificial intelligence (AI) technology is bringing us closer to a future where we will be able to treat a wide range of critical diseases in a targeted, patient-specific way. We see an immense market for new, efficient and personalized drugs, as well as a substantial way to improve patients' quality of life. This is why our purpose is saving lives with AI-powered immunotherapies.
How we do it
At Evaxion, our AI-powered immunotherapies are at the heart of our work to revolutionize drug development and ultimately save the lives of patients. We bridge AI technology, bioinformatics, and drug development to bring novel immunotherapies to patients. We have used our AI to generate a broad pipeline of candidate immunotherapies that address two of the most significant unmet medical needs worldwide – cancer and infectious diseases.
The predictive power of our AI platforms comes from our ability to process and interpret vast amounts of data. These data are transformed into advanced algorithms that we believe can accurately predict cellular interactions and identify the right target to stimulate a relevant, potentially lifesaving, response.
See our latest corporate presentation here.
Leadership Team Evaxion is comprised of an experienced leadership team and advisors with a proven track record from leading pharmaceutical companies and universities.
Per, MD, PhD, joined Evaxion in 2022. He is a board certified physician and associate professor in clinical pharmacology from Lund University, Sweden. Per has more than 20 years of experience from clinical drug development, within both big pharma and biotech companies, with a focus on immuno-oncology. He has held multiple executive leadership positions during the last 14 years. Most recently as Chief Executive Officer at Targinta AB and, prior to that, Chief Executive Officer and Chief Medical Officer at Alligator Bioscience AB. Further, Dr Norlén has extensive business development experience and has entered into several major agreements with international biotech companies and big pharma.
Andreas Holm Mattsson
Andreas is an experienced bioinformatician from the Technical University of Denmark. Prior to Evaxion, Andreas spent six years at Novo Nordisk developing in silico platforms.
Since the founding of Evaxion in 2008, Andreas has worked on developing Evaxion's in silico platforms, including PIONEER and EDEN, and numerous other in silico tools enabling vaccine discovery in the area of infectious diseases and immuno-oncology.
Erik received his MD from the University of Copenhagen and subsequently earned a PhD, became a board certified medical specialist, and was awarded a Doctorate Dissertation (DMSc). He also holds an Executive Master of Business Strategy from Copenhagen Business School.
He has held numerous research and clinical positions, and was a medical manager at Statens Serum Institute. Over the past 15 years, he has gained profound experience in leadership, project management, clinical development and medical affairs during tenures at Bavarian Nordic, Sandia National Laboratories, Novo Nordisk, Novartis and Seagen.
Birgitte Rønø, PhD, joined Evaxion as Senior Director of Immuno-Oncology in 2017 and was appointed Chief Scientific Officer in September 2021.
Dr. Rønø has more than 15 years' experience in biopharmaceutical drug discovery from academia and industry and received her PhD in experimental oncology and immunology from National Institutes of Health, Bethesda, USA, and Copenhagen University Hospital, Denmark.
Bo Karmark is an experienced CFO and has been a member of executive management in a number of multinational companies within production, B2B, service industry, R&D, and consulting, with a documented ability to streamline, simplify, and uniform. He has operational experience from a successful IPO, has conducted several financing rounds and refinancings, and has experience within M&A.
Jesper Nyegaard Nissen
For over 25 years, Jesper Nyegaard Nissen has worked broadly across the pharma value chain in global operations positions anchored in research, development and finance. He has transformed more than 15 business areas across a variety of focus points, including external innovation and collaborations, digitalization of business processes, development and shaping of organizational capacities, and implementation of performance and process improvement structures.
Board of Directors Evaxion is comprised of an experienced leadership team and advisors with a proven track record from leading pharmaceutical companies and universities.
Mrs. Søgaard served for 22 years at the Kammeradvokaten/Law Firm Poul Schmith as a corporate lawyer, partner and board member. After making partner in January of 2000, Mrs. Søgaard primarily worked with technology and processes to acquire technology solutions at the firm and ultimately served on the firm’s board of directors beginning in 2014. After leaving the firm in 2017, Mrs. Søgaard served on various boards including How to Robot, a platform company supporting the acquisition of physical robots for customers and suppliers and Altapay, a payment solution company. From 2018 to 2020, Mrs. Søgaard joined Evaxion Biotech and served as an executive, corporate lawyer and legal advisor to the company.
Steven is the former Senior Vice President of R&D and Head of Infectious Disease & Vaccines at MedImmune, retired April 2018. Prior to working at MedImmune, Steve served as Vice President of Global and Head of Infectious Disease at Novartis, and Vice President and Head of Biological Technologies at Wyeth. Steven is an expert in infectious diseases, having worked many years with both basic and applied research, successfully led four programs resulting in the approval of novel anti-infective drugs with other in various stages of development, and produced more than 110 peer-reviewed publications.
Roberto Prego Pineda
Roberto was one of the first external investors in Evaxion. Roberto has over 20 years of pharmaceutical experience. He has been country GM and also occupied the position of Regional Leader of the Latin American Region for Teva from 2013 until 2015. He currently manages Viax Dental Technologies, an R&D venture in the dental field. He has a B.S. of Economics from Universidad Católica Andrés Bello in Caracas, Venezuela and an MBA from Fuqua School of Business at Duke University.
Lars served for 35 years as an employee and partner of PwC in Denmark, including four years as Chairman of the Board. His clients included a number of major Danish pharmaceutical and biotech companies, where he advised Boards and executives on management remuneration. He currently serves on the Boards of a number of companies, including Gaming Investment A/S and MTI Caretag Invest A/S, both of which as Chairman, and Ascendis Pharma A/S, a U.S. publicly traded company listed on the NASDAQ, as a Board member, Audit Committee Chair and member of the Remuneration Committee.
Niels Iversen Moeller
Niels received his MD from the University of Copenhagen and BA of Economics from Copenhagen Business School. He has worked as a Medical Director within the area of Companion Diagnostics and prior to that as a Medical Advisor within the area of cancer and biopharmaceuticals for AstraZeneca. Niels began this career at Servier Pharmaceuticals as Marketing Manager. Until August 2017, Niels was CEO of Evaxion, and in 2016, he was awarded “CEO of the Year” in the vaccine industry by European CEO.
Advisors Evaxion is comprised of an experienced leadership team and advisors with a proven track record from leading pharmaceutical companies and universities.
Jeffrey S. Weber
Jeffrey S. Weber is the Professor of oncology and the Deputy Director of Perlmutter, Co-Director of the Melanoma Program at the New York University (NYI)-Langone Cancer Center and Head of Experimental Therapeutics at the NYU Langone Medical Center LLC.
Georgina Long is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. Long has been recognized with multiple awards for her research. She is the author of over 360 peer-reviewed publications in melanoma clinical and translational research. She is Past President of Society for Melanoma Research (2020-2022), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020) Scientific Committee for Melanoma/Skin cancer, and is member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024), is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.
Patrick Ott is the Clinical Director of the Melanoma Disease Center and the Center for Immuno-Oncology at Dana-Farber Cancer Institute. He also serves as an attending physician in the Department of Medicine at Brigham and Women's Hospital and has an appointment as Associate Professor at Harvard Medical School in Boston, MA. Ott has been the Principal Investigator and co-investigator in more than 30 treatment trials, including a first in man clinical trial testing a personalized neoantigen vaccine (NeoVax) in patients with melanoma.
Anthony Purcell is an immunologist and a peptide biochemist. Having spent 23 years across both disciplines, he is a leader in the field on ligand/MHC binding mass spec. Tony is currently an NHMRC Principal Research Fellow and Deputy Head (Research) of the Department of Biochemistry at Monash University, an executive committee member of the Australasian Proteomics Society and the Australasian Peptide Society and a member of the Human Proteome Organisation (HUPO) Council. In addition, Anthony is a Visiting Professor in Cancer Science at the University of Southampton (UK).
Kirsten Drejer is a highly respected name in pharma and biotech community. She is best known for being co-founder and CEO of Symphogen A/S. Prior to co-founding Symphogen in 2000, Kirsten held several scientific and managerial positions at Novo Nordisk A/S, including four years as Director of Diabetes Discovery, and three years as Corporate Facilitator. Kirsten is member of the board of directors of a number of biotech and pharma companies, including Zealand Pharma and Antag Therapeutics.
Michael W. Washabaugh
Michael W. Washabaugh is a global leader for therapeutic protein and vaccine development with a broad span of influence and responsibility, involving novel products. He has previously held positions in Adello Biologics (CSO), MedImmunne (Senior Director, Research & Development), Merck & Co Inc. (Senior Director, Head of Biologics and Vaccine Analytical Science and has supported several launched products (US, EU & ROW) including eight vaccines, two monoclonal antibodies, two proteins and two drugs.
Søren Brunak is rated as one of the Worlds 200 most influential biology and biochemistry scientists.
He is the founding Director of the Center for Biological Sequence Analysis, which was formed in 1993 as a multi-disciplinary research group of molecular biologists, biochemists, medical doctors, physicists, and computer scientists.
Søren is professor of Bioinformatics at the Technical University of Denmark and professor of Disease Systems Biology at the University of Copenhagen.
Søren has been highly active within biological data integration, where machine learning techniques often have been used to integrate predicted or established functional genome, metagenome and proteome annotation. Søren is further a member of the Nobel Award Panel.
Christian Schilling, MD, PhD is Managing Partner at AVANTECA Partners AG, a privately held asset management company based in Basel, Switzerland. He is a former senior executive of Boehringer Ingelheim and has over 25 years of experience in Big Pharma, including strategic and operational roles in research, clinical development, marketing and sales as well as country management. He also held executive roles in business development and M&A.
Andrew C. Weber
Andrew C. Weber is a former senior fellow at Belfer Center for Science and International Affairs, Harvard University and the former deputy coordinator for Ebola response at the U.S. Department of State.
From 2009 to 2014, Weber served as Assistant Secretary of Defense for nuclear, chemical, and biological defense programs. Before that, he served as an adviser for threat reduction policy in the office of the Secretary of Defense. Prior to this appointment, Weber was a United States foreign service officer, with diplomatic assignments in Saudi Arabia, Germany, Kazakhstan, and Hong Kong.
Weber has twice been awarded the Exceptional Civilian Service Meda.
Robert J. Palay
Robert J. Palay is Chairman of Tactics II Equity LLC, a life science investment and advisory firm and former Senior Fellow at Harvard’s Advanced Leadership Initiative. Robert is a founder or early stage investor in genomics and stem cell-based companies for over a decade, and from 2004 through 2015 Robert was a founder, Chairman of the Board, and Chief Executive Officer of Cellular Dynamic International (NASDAQ: ICEL), a leader in stem cell manufacturing. In addition, Robert has served as a manager of multiple Tactics II companies, entities specializing in life science investments, been V.P. at Sam Zell’s Equity Group Investments and served on various boards.
Rajeev Surati is an investor and serial entrepreneur in technology and science.
He has built several successful companies, been involved in some of the first successes in instant messaging and photo sharing on the web and been granted five patens including the core patent for Scalable Display Technologies. In addition, Rajeev has both advised and invested in a number of startup companies. Recently, he has focused his attention to healthcare and synthetic biology both as an investor and a data science mentor at Harvard Medical School.
Thomas Wylonis was Chairman of the Board of Evaxion from 2015 to 2020. Tom brings many years of experience to Evaxion as an investor and board member of several life science companies as well as his time working on strategic projects at Bell Labs. Tom is active as a mentor-instructor at MIT and is also a mentor to Penn State engineering students. Tom is also a former Global Director at McKinsey & Company.
Jürgen Langhärig holds a Doctor’s Degree in Biotechnology from the University of Tübingen/Germany an executive MBA from the University of St. Gallen/Switzerland. He is a well-respected name in pharma and biotech Business Development community with over 40 years of experience.
He held business development and managerial positions at Evaxion Biotech A/S (until March 2022), Serodus ASA, Bavarian Nordic A/S, Zealand Pharma A/S, Novo Nordisk A/S, Nycomed Pharma (now Takeda) and Sandoz AG (now Novartis).
Partnerships Strength in collaboration. We have high aspirations, and we are not going to revolutionize drug development on our own. With our promising pipeline of several flagship projects, we are now partnering to scale up and accelerate our clinical trials.
Partner with Evaxion
If you'd like to learn more about partnerships, you can get in touch with Neil Anderson at email@example.com
Play an instrumental role in the expansion of Evaxion and explore our open positions. At Evaxion, you will work in a fast-paced environment that cultivates a collaborative and innovative spirit. We support one another’s growth and success and believe our core is built upon diverse abilities.
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.